Luxeptinib

DB19179InvestigationalSmall molecule

Luxeptinib: Overview.

Chemical structure of Luxeptinib
Formula / weight
C25H17F4N5O2 · 495.438 g/mol (avg)
Also known as
32,72,74,76-tetrafluoro-14-methyl-21,23-dihydro-11h-4,6-diaza-2(4,7)-isoindola- 1(2)-imidazola-3(1,4),7(1)-dibenzenaheptaphane-2,35-dione · Urea, n-(4-(2,3-dihydro-7-(5-methyl-1h-imidazol-2-yl)-1-oxo-1h-isoindol-4-yl)-3-fluorophenyl)-n'-(2,4,6-trifluorophenyl)-
Code names
CG-026806 · CG-806

Resolves to

Compound
UNIITQ6PBX1JU0CAS1616428-23-9ChEMBLCHEMBL4594420
Structure
InChIKeyMWHHJYUHCZWSLS-UHFFFAOYSA-NSMILESCC1=CNC(=N1)C1=CC=C(C2=C1C(=O)NC2)C1=CC=C(NC(=O)NC2=C(F)C=C(F)C=C2F)C=C1F
Targets
Q06187BTK

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Luxeptinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In